Nasdaq · CIK 0001595097
CRBP Corbus Pharmaceuticals Holdings, Inc.
Insider trading from SEC Form 4. Last filing 27 d ago. Close $5.38 on Oct 9, 2026, +2% from the 52-week low and -72% from the high.
Last 90 days
Net insider value
-$16k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$16k by 1 insider
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
CRBPOct 9, 2026 · close 5.38
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Corbus Pharmaceuticals Holdings, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Yong Ben director sell | $16k 2,000 shares | -18% | - | |
| 27Weak | Cormorant Asset Management, LP owner sell | $344k 30,029 shares | -1% | +97% from low-50% from high | |
| 27Weak | Yuval Cohen Chief Executive Officer sell | $471k 27,633 shares | -18% | +243% from low-13% from high | |
| 19Weak | Sean F. Moran Chief Financial Officer sell | $221k 12,981 shares | -15% | +243% from low-13% from high | |
| 0Weak | Anne Altmeyer director sell | $22k 1,060 shares | -15% | +272% from low-5% from high | |
| 23Weak | Anne Altmeyer director sell | $10k 1,392 shares | -50% | +51% from low-87% from high | |
| 23Weak | John Kenneth Jenkins director sell | $20k 2,783 shares | -99% | +51% from low-87% from high | |
| 21Weak | Dominic Smethurst Chief Medical Officer sell | $43k 6,393 shares | -8% | - | |
| 20Weak | Yuval Cohen Chief Executive Officer sell | $62k 7,134 shares | -5% | - | |
| 10Weak | Sean F. Moran Chief Financial Officer sell | $24k 2,792 shares | -4% | - |
Transactions
The last 37 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Yong Ben director | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -2,000 | $7.84 | $16k | 9,383 | 27 d ago |
| Dec 11, 2025 | Cormorant Asset Management, LP owner | SOpen-market sale Common Stockindirect: See Footnotes | -30,029 | $11.46 | $344k | 2,344,971 | Dec 15, 2025 |
| Oct 24, 2025 | Yuval Cohen Chief Executive Officer | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +18,660 | $4.26 | $79k | 156,847 | Oct 27, 2025 |
| Oct 24, 2025 | Sean F. Moran Chief Financial Officer | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +12,981 | $4.26 | $55k | 86,294 | Oct 27, 2025 |
| Oct 24, 2025 | Yuval Cohen Chief Executive Officer | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -18,660 | $17.01 | $317k | 138,187 | Oct 27, 2025 |
| Oct 24, 2025 | Sean F. Moran Chief Financial Officer | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -12,981 | $17.02 | $221k | 73,313 | Oct 27, 2025 |
| Oct 27, 2025 | Yuval Cohen Chief Executive Officer | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +8,973 | $4.26 | $38k | 147,160 | Oct 27, 2025 |
| Oct 24, 2025 | Sean F. Moran Chief Financial Officer | MOption exercise Stock options (right to buy)derivative10b5-1 | -12,981 | $0.00 | $0 | 10,386 | Oct 27, 2025 |
| Oct 27, 2025 | Yuval Cohen Chief Executive Officer | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -8,973 | $17.14 | $154k | 138,187 | Oct 27, 2025 |
| Oct 24, 2025 | Yuval Cohen Chief Executive Officer | MOption exercise Stock options (right to buy)derivative10b5-1 | -18,660 | $0.00 | $0 | 31,079 | Oct 27, 2025 |
| Oct 27, 2025 | Yuval Cohen Chief Executive Officer | MOption exercise Stock options (right to buy)derivative10b5-1 | -8,973 | $0.00 | $0 | 22,106 | Oct 27, 2025 |
| Oct 20, 2025 | Anne Altmeyer director | MOption exercise Common Stock, par value $0.0001 per share10b5-1 | +1,060 | $4.80 | $5,088 | 7,251 | Oct 21, 2025 |
| Oct 20, 2025 | Anne Altmeyer director | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -1,060 | $20.50 | $22k | 6,191 | Oct 21, 2025 |
| Oct 20, 2025 | Anne Altmeyer director | MOption exercise Stock options (right to buy)derivative10b5-1 | -1,060 | $0.00 | $0 | 4,247 | Oct 21, 2025 |
| May 30, 2025 | Anne Altmeyer director | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -1,392 | $7.25 | $10k | 1,391 | Jun 2, 2025 |
| May 30, 2025 | Winston Kung director | AGrant or award Common Stock, par value $0.0001 per share | +4,800 | $0.00 | $0 | 10,366 | Jun 2, 2025 |
| May 30, 2025 | Yong Ben director | AGrant or award Common Stock, par value $0.0001 per share | +4,800 | $0.00 | $0 | 7,583 | Jun 2, 2025 |
| May 30, 2025 | Rachelle Suzanne Jacques director | AGrant or award Common Stock, par value $0.0001 per share | +4,800 | $0.00 | $0 | 7,583 | Jun 2, 2025 |
| May 30, 2025 | Alan F Holmer director | AGrant or award Common Stock, par value $0.0001 per share | +4,800 | $0.00 | $0 | 10,629 | Jun 2, 2025 |
| May 30, 2025 | John Kenneth Jenkins director | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -2,783 | $7.35 | $20k | 33 | Jun 2, 2025 |
| May 30, 2025 | Winston Kung director | AGrant or award Stock options (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Yong Ben director | AGrant or award Stock options (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | John Kenneth Jenkins director | AGrant or award Common Stock, par value $0.0001 per share10b5-1 | +4,800 | $0.00 | $0 | 4,833 | Jun 2, 2025 |
| May 30, 2025 | Alan F Holmer director | AGrant or award Stock options (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Rachelle Suzanne Jacques director | AGrant or award Stock options (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Anne Altmeyer director | AGrant or award Common Stock, par value $0.0001 per share10b5-1 | +4,800 | $0.00 | $0 | 6,191 | Jun 2, 2025 |
| May 30, 2025 | John Kenneth Jenkins director | AGrant or award Stock options (right to buy)derivative10b5-1 | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Anne Altmeyer director | AGrant or award Stock options (right to buy)derivative10b5-1 | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| Mar 6, 2025 | Dominic Smethurst Chief Medical Officer | SOpen-market sale Common Stock, par value $0.0001 per share | -6,393 | $6.78 | $43k | 70,807 | Mar 7, 2025 |
| Feb 14, 2025 | Yuval Cohen Chief Executive Officer | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -7,134 | $8.76 | $62k | 138,187 | Feb 18, 2025 |
| Feb 14, 2025 | Sean F. Moran Chief Financial Officer | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -2,792 | $8.76 | $24k | 73,313 | Feb 18, 2025 |
| Jan 31, 2025 | Yuval Cohen Chief Executive Officer | AGrant or award Common Stock, par value $0.0001 per share | +68,100 | $0.00 | $0 | 145,321 | Feb 4, 2025 |
| Jan 31, 2025 | Sean F. Moran Chief Financial Officer | AGrant or award Common Stock, par value $0.0001 per share | +27,500 | $0.00 | $0 | 76,105 | Feb 4, 2025 |
| Jan 31, 2025 | Dominic Smethurst Chief Medical Officer | AGrant or award Common Stock, par value $0.0001 per share | +27,200 | $0.00 | $0 | 77,200 | Feb 4, 2025 |
| Jan 31, 2025 | Yuval Cohen Chief Executive Officer | AGrant or award Stock options (right to buy)derivative | +228,800 | $0.00 | $0 | 228,800 | Feb 4, 2025 |
| Jan 31, 2025 | Sean F. Moran Chief Financial Officer | AGrant or award Stock options (right to buy)derivative | +92,500 | $0.00 | $0 | 92,500 | Feb 4, 2025 |
| Jan 31, 2025 | Dominic Smethurst Chief Medical Officer | AGrant or award Stock options (right to buy)derivative | +91,200 | $0.00 | $0 | 91,200 | Feb 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Anne Altmeyerdirector
- Yong Bendirector, officer
- Yuval CohenChief Executive Officer
- Cormorant Asset Management, LPowner, other
- Alan F Holmerdirector
- Rachelle Suzanne Jacquesdirector
- John Kenneth Jenkinsdirector
- Winston Kungcfo, officer, director
- Sean F. MoranChief Financial Officer
- Dominic SmethurstChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.